SG11202002475TA - Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals - Google Patents
Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animalsInfo
- Publication number
- SG11202002475TA SG11202002475TA SG11202002475TA SG11202002475TA SG11202002475TA SG 11202002475T A SG11202002475T A SG 11202002475TA SG 11202002475T A SG11202002475T A SG 11202002475TA SG 11202002475T A SG11202002475T A SG 11202002475TA SG 11202002475T A SG11202002475T A SG 11202002475TA
- Authority
- SG
- Singapore
- Prior art keywords
- animals
- diseases
- prevention
- treatment
- fused heteroaromatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17197344 | 2017-10-19 | ||
| PCT/EP2018/078086 WO2019076817A1 (en) | 2017-10-19 | 2018-10-15 | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002475TA true SG11202002475TA (en) | 2020-04-29 |
Family
ID=60143623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002475TA SG11202002475TA (en) | 2017-10-19 | 2018-10-15 | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11077111B2 (en) |
| EP (1) | EP3665171A1 (en) |
| JP (1) | JP2020537678A (en) |
| KR (1) | KR20200073216A (en) |
| CN (1) | CN111194319A (en) |
| AU (1) | AU2018350683A1 (en) |
| BR (1) | BR112020007679A2 (en) |
| CA (1) | CA3079292A1 (en) |
| CL (1) | CL2020001036A1 (en) |
| DO (1) | DOP2020000093A (en) |
| IL (1) | IL273834A (en) |
| MX (1) | MX2020004155A (en) |
| PH (1) | PH12020550444A1 (en) |
| RU (1) | RU2020116178A (en) |
| SG (1) | SG11202002475TA (en) |
| TW (1) | TW201922744A (en) |
| UY (1) | UY37945A (en) |
| WO (1) | WO2019076817A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043437A (en) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | Heterocylic compound as a protein kinase inhibitor |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6797706B1 (en) | 1999-06-09 | 2004-09-28 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclecarboxamide derivative |
| GB9918035D0 (en) | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| JP2001302667A (en) | 2000-04-28 | 2001-10-31 | Bayer Ag | Imidazopyrimidine derivative and triazolopyrimidine derivative |
| US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7276502B2 (en) | 2003-03-25 | 2007-10-02 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| PL1656372T3 (en) | 2003-07-30 | 2013-08-30 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| WO2006129100A1 (en) | 2005-06-03 | 2006-12-07 | Glaxo Group Limited | Novel compounds |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| MX2009002377A (en) | 2006-09-07 | 2009-03-13 | Biogen Idec Inc | Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase. |
| EP3023422A1 (en) | 2007-03-12 | 2016-05-25 | YM BioSciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| EA024109B1 (en) | 2008-04-16 | 2016-08-31 | Портола Фармасьютиклз, Инк. | Protein kinases inhibitors |
| KR20170051521A (en) | 2008-04-16 | 2017-05-11 | 포톨라 파마슈티컬스, 인코포레이티드 | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
| MX2011006091A (en) | 2008-12-08 | 2011-11-29 | Gilead Connecticut Inc | Imidazopyrazine syk inhibitors. |
| EP2513098B1 (en) | 2009-12-17 | 2016-11-09 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| BR112012015651B1 (en) * | 2009-12-23 | 2021-10-26 | Takeda Pharmaceutical Company Limited | FOUNDED HETEROAROMATIC PYRROLIDINAN COMPOUND, ITS PHARMACEUTICAL COMPOSITION, ITS USE AND COMBINATION |
| EP2655357B1 (en) | 2010-12-20 | 2016-06-22 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| EP2723739B1 (en) * | 2011-06-22 | 2016-08-24 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| TWI735853B (en) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | Syk inhibitors |
| EP3110820B1 (en) * | 2014-02-28 | 2022-04-06 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| PE20171179A1 (en) | 2014-12-18 | 2017-08-22 | Takeda Pharmaceuticals Co | SOLID STATE FORMS OF FUSED HETEROAROMATIC PYRROLIDINONES |
| US20160251376A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| ES2898771T3 (en) | 2016-06-01 | 2022-03-08 | Bayer Animal Health Gmbh | Substituted indazoles useful for the treatment and prevention of allergic and/or inflammatory diseases in animals |
-
2018
- 2018-10-15 AU AU2018350683A patent/AU2018350683A1/en not_active Abandoned
- 2018-10-15 SG SG11202002475TA patent/SG11202002475TA/en unknown
- 2018-10-15 EP EP18789357.3A patent/EP3665171A1/en active Pending
- 2018-10-15 CN CN201880066927.1A patent/CN111194319A/en active Pending
- 2018-10-15 JP JP2020522063A patent/JP2020537678A/en active Pending
- 2018-10-15 RU RU2020116178A patent/RU2020116178A/en unknown
- 2018-10-15 CA CA3079292A patent/CA3079292A1/en not_active Abandoned
- 2018-10-15 KR KR1020207010793A patent/KR20200073216A/en unknown
- 2018-10-15 BR BR112020007679-1A patent/BR112020007679A2/en unknown
- 2018-10-15 US US16/757,083 patent/US11077111B2/en active Active
- 2018-10-15 WO PCT/EP2018/078086 patent/WO2019076817A1/en unknown
- 2018-10-15 MX MX2020004155A patent/MX2020004155A/en unknown
- 2018-10-18 TW TW107136707A patent/TW201922744A/en unknown
- 2018-10-19 UY UY0001037945A patent/UY37945A/en not_active Application Discontinuation
-
2020
- 2020-04-06 IL IL273834A patent/IL273834A/en unknown
- 2020-04-17 CL CL2020001036A patent/CL2020001036A1/en unknown
- 2020-04-17 PH PH12020550444A patent/PH12020550444A1/en unknown
- 2020-05-22 DO DO2020000093A patent/DOP2020000093A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3079292A1 (en) | 2019-04-25 |
| IL273834A (en) | 2020-05-31 |
| KR20200073216A (en) | 2020-06-23 |
| AU2018350683A1 (en) | 2020-04-02 |
| BR112020007679A2 (en) | 2020-10-20 |
| RU2020116178A (en) | 2021-11-19 |
| TW201922744A (en) | 2019-06-16 |
| CL2020001036A1 (en) | 2020-10-23 |
| JP2020537678A (en) | 2020-12-24 |
| UY37945A (en) | 2019-05-31 |
| PH12020550444A1 (en) | 2021-04-26 |
| WO2019076817A1 (en) | 2019-04-25 |
| CN111194319A (en) | 2020-05-22 |
| US11077111B2 (en) | 2021-08-03 |
| DOP2020000093A (en) | 2020-09-30 |
| MX2020004155A (en) | 2020-08-03 |
| EP3665171A1 (en) | 2020-06-17 |
| US20200261461A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258588A1 (en) | Compounds and formulations for treating ophthalmic diseases | |
| IL246564A (en) | 3-aryl-1-heterocyclyl-pyrazolo[3,4-d]pyrimidine derivatives and use thereof in the treatment of diseases | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| IL263132B (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| IL265955A (en) | Therapeutic compounds and methods of use thereof | |
| IL274578A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| SG10201402819WA (en) | Composition for prevention and treatment of joint pain and the method of preparation thereof | |
| ZA201804950B (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| IL264069A (en) | Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| GB201617064D0 (en) | Compounds and their therapeutic use | |
| HK1257236A1 (en) | Medicine for preventing and treating hyperlipemia diseases and use of the medicine | |
| GB201715194D0 (en) | Compounds and their therapeutic use | |
| HK1257585A1 (en) | Medicine for preventing and treating skin fibrosis and use of the medicine | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| IL272495A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| IL273834A (en) | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals | |
| PT3120852T (en) | Preventive and/or therapeutic agent for immune diseases | |
| HUE056301T2 (en) | Salt of substituted urea derivative and use thereof in medicine | |
| PL3515409T3 (en) | Complex and compositions for the treatment of ophthalmic and dermatological diseases | |
| EP3377062C0 (en) | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | |
| IL259383A (en) | Compound for use in the prevention and treatment of neurodegenerative diseases | |
| RS65201B1 (en) | Indoline derivatives for treatment and/or prevention of fibrosis diseases | |
| EP3272349A4 (en) | Therapeutic and/or prophylactic agent for lewy body diseases | |
| GB201410869D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |